Result Oriented Integrative Medicine
CHIPSA has an extensive "arsenal" to build the body's immune defense mechanisms as well as to attack disease itself.
Among many of the diseases that have been treated successfully at CHIPSA and The Center for Integrative Medicine are those listed below
on this treatment page.
before and following surgery, radiation and chemotherapy significantly reduce the incidence of relapse and raises the remission rates in most cancers. During immunological treatment, cancer patients experience relief from a vast variety of chronic conditions that have been resistant to standard treatment. We also include our licensed Gerson Therapy as a detoxification protocol for receptive preparation of the following medical protocols that are planned as part of a patient's treatment regime.
The two-fold basis of integrative care is directed at individuals comprising:
Both standard and complimentary methods directed at the elimination of malignant cells, as well as;
A system of non-specific immunological treatment modalities aimed at the restoration of the internal milieu and enhancement of the natural defense and repair mechanisms of the whole person.
Cancer is a degenerative disease arising in the following phases:
Causal factors, leading to
Secondary damage, leading to
Disease milieu and lowered resistance, leading to
Susceptibility to infection and pathological change, leading to
Disease symptoms (including the formation of tumors).
A Tumor Board
has been created by leveraging cumulative years of oncology experience. The Tumor Board meets frequently to assess, chart-by-chart, the special needs of current and prospective patients.
The CHIPSA integrative treatment protocol saves individuals lives by:
of all known causal factors;
to causal factors;
of secondary damage to host metabolism by dietotherapy and supportive treatments, the correction of acid-base derailment by treatment of serum alkalosis and tissue acidosis, hyperthermia, fever therapy, oxygenation treatment, ultraviolet blood irradiation (UVB), extracorpeal-photopheresis( ECP), enzymes, glandular, organ extracts, neural therapy and,
4) Personalized vaccine
and/or tissue regeneration
: Clinical observation and statistical analyses have revealed that individualized immunity procedures and tissue regenerative medicine when addressing degenerative disease provide positive outcomes when all 'standard treatments' have been exhausted. Immunological modalities improve general condition, prolong life and in a variety of cases, achieve complete long-term remission.
As early as 1928, German neurosurgeon Max Gerson's nutritional immunotherapeutic management was hailed as an anti-infective treatment curative of tuberculosis of the skin in far-advanced patients who could not be helped by any other treatments. Pursuant to this, the world medical literature was flooded with positive reports from the majority of leading investigators of the developed countries as the treatment was applied to a wide range of diseases. Gerson, and later others, found this approach could benefit cancer patients, sometimes with remarkable outcomes.
In order to treat more advanced disease, Gerson developed a detoxification program capable of managing cancer pain and disease toxicity. Through this approach it became possible to wean even far-advanced patients off of opiate analgesics, e.g., morphine. Experience has led CHIPSA's medical team to believe that nutritional immunotherapy with detoxification both enables and potentiate vaccine-induced anti-cancer immunities.
Coley Fluid is the most effective single-agent therapeutic vaccine for cancer in the history of modern medicine. Currently manufactured with a high-degree of technical sophistication by a modern Canadian bio-tech corporation, MBVax Bioscience (http://www.mbvax.com), Coley Fluid anchors CHIPSA's vaccine-based cancer immunotherapy. Top of page
Psoralin Ultraviolet A (PUVA) photopheresis was originally approved by the US Food & Drug Administration (FDA) in the 1980s for the treatment of T-cell lymphoma. Recent improved understanding of its mechanisms of action has allowed its application to other cancers. Importantly, PUVA photopheresis can be used to amplify, and to make more specific, the central mechanisms of Coley Fluid when the two treatments are integrated.
DENDRITIC CELLS (DC):
Because cancer-patient dendritic cell populations are both sparse and suppressed, early attempts to vaccinate cancer patients with killed-cells from their own tumors mostly failed to provoke anti-tumor lymphocyte activity. With only simple modifications, PUVA photopheresis can be used to both amplify and stimulate DC populations which, in turn, activate anti-tumor lymphocytes. When it is possible to retrieve a small sample of tumor from the patient, malignant tissue can be killed, broken down, and fed to culturing DCs that can be returned to the patient to provoke specific anti-tumor immunities. When used in conjunction with Coley Fluid, tumor-loaded DCs increase the likelihood that tumors will be completely cleared. Top of page
MAXILLOFACIAL FOCI REVIEW:
This set of diagnostic procedures includes the biological dentist and several surgeons. In the mouth, root canals, devitalized teeth, and silver amalgams are considered. In the nose and throat, sinuses, tonsils, and adenoids will be examined. Top of page
First reported in 1965 to enhance the cancer killing effect of radiotherapy, its regular application at CHIPSA is based on the observation that patients experience enhancement of subjective sense of well being. More recently the possibility has been raised that administration of oxygen radicals may compensate, at least in part, for the failure of P-53 gene expression thereby encouraging cancer cell apoptosis (cell suicide). Ozone is administered topically, rectally, and intravenously (during UVB). Scheduled 2 times per day with 60 cc of Ozone gas at approx 64-72 micrograms/milliliter and is administered rectally. Top of page
: Whole-body hyperthermia through immersion hydrotherapy has been long-recognized for its many beneficial therapeutic effects including improved circulation and stimulation of disease-fighting capabilities. Recently it has been demonstrated to promote anti-cancer immunities. Top of page
UREA / CREATINE:
Danopoulos published in respected journals many provocative reports of tumor responses to synthetic urea and creatine. CHIPSA physicians have merged Danopoulos' protocols with the much higher dosages used safely by Nalbadian. This treatment is an important alternative method of tumor debulking. Top of page
An experimental vaccine aimed at prevention of tumor recurrence. Stemming from Govallo's Russian-certified vaccination to cure chronic miscarriages, injectable placental extracts exploit similarities between tumor immune-masking and placental protection against rejection.
CANCER-ASSOCIATED-MICROBE VACCINE (CAMV):
Microbes found in all healthy people (aiding digestion and immunity) are recruited by malignant cells to work for and become a part of cancerous growths. It is possible to make an autologous vaccine from their identifying proteins (antigens) that can suppress their over-colonization and pathological behavior.
Wolf & Benitez ("Wobe¨) proposed the use of a variety of enzymes in high doses to combat malignancies. Preliminary findings in Germany are encouraging. Top of page
GLUCOSE-POTASSIUM-INSULIN (GKI) POLARIZING THERAPY:
GKI therapy was developed by renowned cardiologist Demetrio Sodi-Pallares. Treatment with GKI reduces morbidity and mortality in patients with advanced disease, in addition to controlling cancer pain and contributing to tumor reduction. Recent science has elucidated the role of GKI in strengthening and sustaining immune responses to vaccine-and nutrition-based immunotherapy.
This vitamin has shown a strong anti-tumor effect in a breast cancer trial (Copenhagen, Denmark). Principal investigator Karl Folkers reports regression of liver and lung tumors in a current German trial.
Historically, Prudden demonstrated that cartilage extracts from the tracheal rings of young calves accelerates and strengthens surgical wound healing, provides beneficial effect in arthritis, and is curative malignant psoriasis. He published anti-tumor effects in 1985, and is conducting a current trial showing promise in advanced kidney cancer. Other cartilage extracts are in various stages of development. Top of page
A small amount of patient's blood is removed, allowed to break down to release intracellular forms, and injected intramuscularly.
These treatments (calcitonin, clodronate, pamidronate, etc.) can heal cancer-damaged bones.
CHIPSA - Centro Hospitalario Internacional Pacifico, SA is the Mexico Center for Integrative Medicine practicing alternative and complementary medical care. Offering a modern, 6 story hospital housing 70 beds with accompany four-bed intensive-care unit, a full-service surgical ER staff and suite, birthing facilities, state-of-the art anesthesiology, immersion hyperthermia technology, alternative medical research laboratory, x-ray, ultrasound and a 24-hour emergency room. CHIPSA is a community hospital serving the local populations primary care needs, including birthing and emergencies. CHIPSA provides medical care for several regional corporations. The Gerson Plus Program reserves beds for patients arriving from all over the world, seeking treatment of degenerative diseases with the many integrated therapeutic offerings. CHIPSA hospital is a fully accredited, intensive-care, registered facility.
The CHIPSA Gerson Hospital is the founding medical institution of the Gerson+Therapy developed by Max B. Gerson, MD, founder of Immunonutrition, who is known for his many contributions in chronic and degenerative infectious diseases, as well as the treatment for cancer. CHIPSA is devoted to integrative medicine and is the most experienced hospital practicing complementary and immunonutrition and detoxification therapy on the Pacific Rim.
CHIPSA Hospital, #670, Colonia Jardines del Sol, Playas Tijuana, Mexico C.P. 22700
This site or parts thereof may be linked to for reference only and may not be duplicated in any manner without permission with CHIPSA and the Executive Director of CHIPSA.
C.H.I.P.S.A. All rights reserved. / Marca Registrada: #512642, #512643, #512646 / copyright 2005